Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Basal Cell 3Basal Cell Nevus Syndrome 3Pancreatic Neoplasms 2Neoplasms 2Head and Neck Neoplasms 1Chondrosarcoma 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 253Radiotherapy 176Cetuximab 145pembrolizumab 120Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 77Radiotherapy, Intensity-Modulated 69Nivolumab 37Radiation 30Drug Therapy 30Erlotinib Hydrochloride 26Gemcitabine 25Cyclophosphamide 22Gefitinib 21Surveys and Questionnaires 20Standard of Care 20Surgical Procedures, Operative 19Pemetrexed 19durvalumab 18Magnetic Resonance Spectroscopy 17Capecitabine 17Radiosurgery 16Celecoxib 16atezolizumab 15Filgrastim 15Amifostine 15130-nm albumin-bound paclitaxel 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Head and Neck Neoplasms × IPI-926 × Clear all
NCT01255800 2014-01-31

Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer

University of Colorado, Denver

Phase 1 Completed
9 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡